Skip to main
ZBIO
ZBIO

ZBIO Stock Forecast & Price Target

ZBIO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zenas BioPharma Inc is strategically positioned to capture a significant share of the estimated $3 billion market opportunity in IgG4-RD, showcasing the potential for robust revenue growth from its proprietary treatment, obexelimab. With approximately $350 million on its balance sheet, the company is well-capitalized to support ongoing clinical trials and navigate multiple upcoming catalyst events anticipated over the next 18 months. Additionally, the differentiated mechanism of action of obexelimab, particularly its dual engagement of CD19 and FcγRIIb, may offer unique advantages in treating autoimmune conditions, thereby enhancing its competitive positioning in the biopharmaceutical landscape.

Bears say

Zenas BioPharma reported a net loss of $52.6 million for the fourth quarter of 2024 and a total yearly loss of $157 million, indicating significant financial strain as it continues its clinical development phase. The company's market position remains precarious due to potential risks, including the possibility that its product candidate obexelimab may fail to meet expected commercial revenue targets, alongside challenges in securing necessary funding to sustain operations. Furthermore, with the stock trading below its cash reserves, Zenas BioPharma faces heightened concerns regarding its ability to compete effectively amid emerging competitors and ongoing R&D setbacks.

ZBIO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zenas Biopharma Inc (ZBIO) Forecast

Analysts have given ZBIO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ZBIO has a Strong Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zenas Biopharma Inc (ZBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.